StemCell Therapy

GlobalChemotherapy Induced Peripheral Neuropathy TreatmentMarket Report 2020, Forecast to 2025presents a historical overview of market size, revenue, share, forecast, and market drivers. The report features detailed insights and deep research on the globalChemotherapy Induced Peripheral Neuropathy Treatmentmarket. The report studies various segments, as well as key opportunities in the market and influencing factors which will help businesses increase their footprints in the industry. A comprehensive analysis of the product scope and market risks has been given for the participants. The report shows the company profile of the major vendors along with their winning strategies to give business owners, stakeholders, and field marketing personal a competitive edge over others operating in the market.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/37081/request-sample

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

The Market Report Addresses:

The report provides historical and forecasts market data including demand, application details, price trends, and company shares of the leading manufacturers by geography, and estimation of the globalChemotherapy Induced Peripheral Neuropathy Treatmentmarket size by volume and value. The growth estimation of the market is offered on the basis of calculation by various segmentation and past and current data. This market has been divided into types, applications, and regions. The report also covers the growth aspects of the market along with the restraining factors which are expected to impact the overall growth of the market in the estimated forecast period from 2020 to 2025.

The top manufacturers/suppliers which are currently operating in the globalChemotherapy Induced Peripheral Neuropathy Treatmentmarket industry includes:Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma

Market Regions and Countries Level Analysis:

Regional analysis is a highly comprehensive section of this report. This segmentation sheds light on the sales of theChemotherapy Induced Peripheral Neuropathy Treatmenton regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. Market segmented by region/country:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-report-37081.html

Moreover, the report aims to deliver evaluation and essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the market. The study recognizes the factors affecting the globalChemotherapy Induced Peripheral Neuropathy Treatmentmarket growth such as drivers, restraints, opportunities, and trends. The report also recognizes emerging players with a potentially strong product portfolio and creates effective counter-strategies to gain competitive advantage. The report features reliable high-quality data and analysis which is suitable for supporting your internal and external presentations. The market research report will also help create regional and country strategies on the basis of local data and analysis.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]Web:www.magnifierresearch.com

Read more:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 with COVID-19 After Effects Analysis by Emerging Trends, Industry Demand,...

The research report on the Diabetic Peripheral Neuropathy Treatment Market offers a comprehensive study on market share, size, growth aspects, and major players. In addition, the report contains brief information about the regional competitive landscape, market trends, and drivers, opportunities and challenges, distributors, sales channels, risks & entry barriers, as well as Porters Five Forces Analysis. Moreover, the main objective of this report is to offer a detailed analysis of how the market aspects potentially influence the coming future of the Diabetic Peripheral Neuropathy Treatment market. The report also offers a comprehensive analysis about the competitive manufacturers as well as the new entrants also studies along with their brief research.

The report includes the latest coverage of the impact of COVID-19 on the Diabetic Peripheral Neuropathy Treatment industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

Get | Download Sample Copy of Diabetic Peripheral Neuropathy Treatment Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=205689&utm_source=NYH&utm_medium=888

In addition, this report also contains a price, revenue, market share, and production of the service providers is also mentioned with accurate data. Moreover, the global Diabetic Peripheral Neuropathy Treatment report majorly focuses on the current developments, new possibilities, advancements, as well as dormant traps. Furthermore, the Diabetic Peripheral Neuropathy Treatment market report offers a complete analysis of the current situation and the advancement possibilities of the Diabetic Peripheral Neuropathy Treatment market across the globe. This report analyses substantial key components such as production, capacity, revenue, price, gross margin, sales revenue, sales volume, growth rate, consumption, import, export, technological developments, supply, and future growth strategies.

We provide a detailed analysis of key players operating in the Diabetic Peripheral Neuropathy Treatment Market:

Moreover, the Diabetic Peripheral Neuropathy Treatment report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Diabetic Peripheral Neuropathy Treatment market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Diabetic Peripheral Neuropathy Treatment market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=205689&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Diabetic Peripheral Neuropathy Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Diabetic Peripheral Neuropathy Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Diabetic Peripheral Neuropathy Treatment Market, By Deployment Model

5.1 Overview

6 Diabetic Peripheral Neuropathy Treatment Market, By Solution

6.1 Overview

7 Diabetic Peripheral Neuropathy Treatment Market, By Vertical

7.1 Overview

8 Diabetic Peripheral Neuropathy Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Diabetic Peripheral Neuropathy Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=205689&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Peripheral Neuropathy Treatment Market Size, Diabetic Peripheral Neuropathy Treatment Market Trends, Diabetic Peripheral Neuropathy Treatment Market Growth, Diabetic Peripheral Neuropathy Treatment Market Forecast, Diabetic Peripheral Neuropathy Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Proppant Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Propyl Acetate Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Protech Textiles Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See more here:
Diabetic Peripheral Neuropathy Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Astellas Pharma

Moreover, the Diabetic Neuropathy Drugs report offers a detailed analysis of the competitive landscape in terms of regions and the major service providers are also highlighted along with attributes of the market overview, business strategies, financials, developments pertaining as well as the product portfolio of the Diabetic Neuropathy Drugs market. Likewise, this report comprises significant data about market segmentation on the basis of type, application, and regional landscape. The Diabetic Neuropathy Drugs market report also provides a brief analysis of the market opportunities and challenges faced by the leading service provides. This report is specially designed to know accurate market insights and market status.

By Regions:

* North America (The US, Canada, and Mexico)

* Europe (Germany, France, the UK, and Rest of the World)

* Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

* Latin America (Brazil and Rest of Latin America.)

* Middle East & Africa (Saudi Arabia, the UAE, , South Africa, and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175788&utm_source=NYH&utm_medium=888

Table of Content

1 Introduction of Diabetic Neuropathy Drugs Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Diabetic Neuropathy Drugs Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Diabetic Neuropathy Drugs Market, By Deployment Model

5.1 Overview

6 Diabetic Neuropathy Drugs Market, By Solution

6.1 Overview

7 Diabetic Neuropathy Drugs Market, By Vertical

7.1 Overview

8 Diabetic Neuropathy Drugs Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Diabetic Neuropathy Drugs Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=175788&utm_source=NYH&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Neuropathy Drugs Market Size, Diabetic Neuropathy Drugs Market Trends, Diabetic Neuropathy Drugs Market Growth, Diabetic Neuropathy Drugs Market Forecast, Diabetic Neuropathy Drugs Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Our Trending Reports

Sensors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

U.S. Pest Control Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the article here:
Diabetic Neuropathy Drugs Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty

Peripheral neuropathy is a common complication of primary Sjgren syndrome and may be associated with a diminished health-related quality of life (HR-QoL), according to research results published in Rheumatology International.

Researchers sought to compare HR-QoL outcomes in patients with primary Sjgren syndrome, both with and without peripheral neuropathy. They also aimed to examine the associations between the neurologic complications and components of HR-QoL outcomes using the 36-item Short Form Health Survey (SF-36). Overall, 50 adult patients with primary Sjgren syndrome (median age, 57.5 years; 96% women) were included in the study.

Of the total cohort, 80% (n=40) reported subjective symptoms, including paresthesia or other symptoms that were suggestive of neuropathic pain on a periodic or permanently present basis. In total, 46% (n=23) of patients met the criteria for a diagnosis of peripheral neuropathy (PNS+); the remaining patients were referred to as PNS-.

Researchers indicated the most common peripheral nervous system manifestation to be sensorimotor neuropathy, which was present in 47% of patients who were PNS+. Mononeuropathy was present in 26%, pure axonal sensory neuropathy, axonal motor neuropathy, and small fiber neuropathy were each present in 4.3%, and cranial nerve involvement was present in 17.4% of patients who were PNS+; 1 patient experienced both cranial and sensorimotor neuropathy. Among 35% of patients who were PNS+, neurologic symptoms preceded patients diagnosis of primary Sjgren syndrome.

Investigators studied data from both groups of patients in terms of clinical characteristics and laboratory testing results, and observed similarity in age, disease duration, time from diagnosis, and time of symptom onset. Clinical manifestations, including parotid enlargement, respiratory tract involvement, lymphadenopathy, and hypocomplementemia were significantly more prevalent among patients who were PNS+ vs those who were PNS- (74% vs 44%; 65% vs 37%; 61% vs 19%; and 26% vs 7%, respectively). In addition, patients in the PNS+ vs PNS- group were statistically significantly more likely to frequently use cyclophosphamide because of extraglandular manifestations (17% vs 0%, respectively).

Both groups were also compared based on the results of the visual analog scale (VAS)-pain scale, SF-36, and an interview regarding pain type. Among patients who were PNS+ vs PNS-, median VAS-pain was 3 vs 0, respectively (range, 0-7; P =.229). Neuropathic type pain was often observed across both subgroups but was predominantly among patients who were PNS+ compared with those who were PNS- (70% vs 41%).

Across the 5 domains of the SF-36, patients who were PNS+ vs PNS- had significantly lower results in terms of physical and emotional roles, vitality, bodily pain, and general health (P .05).

Study limitations included potential referral bias in patient selection, researchers inability to conduct neurophysiologic testing in individuals suspected of pure small-fiber neuropathy, and a lack of unambiguous differentiation between Sjgren syndrome-related neuropathy and other forms of neuropathy.

Our study showed that peripheral nervous involvement is frequent in [patients with primary Sjgren syndrome] and it is correlated with worse HR-QoL, the researchers concluded. To get the complete picture of [patients with Sjgren syndrome], a holistic approach starting with a comprehensive assessment of disease activityis needed.

Reference

Jasklska M, Chylinska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjgrens syndrome: A preliminary report [published online March 14, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04543-2

This article originally appeared on Rheumatology Advisor

Originally posted here:
Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome - Neurology Advisor

Patients with trigeminal nerve damage report moderate-to-severe levels of pain and unpleasantness with evidence for varied site-dependent somatosensory disturbances. This is based on the results of a comprehensive set of psychophysical and electrophysiological investigations published in The Clinical Journal of Pain.

The goal of the current study was to investigate the somatosensory changes related to trigeminal nerve damage using psychophysical and electrophysiological tools.

The study cohort included 37 patients (24 women, mean age 44.6 years) attending Department of Dentistry and Oral Health, Aarhus University, Denmark and Faculty of Odontology, Malm University, Sweden; and Skne University Hospital, Lund, Sweden. Most patients were diagnosed with painful posttraumatic trigeminal neuropathy (n=30), and a minority had nonpainful posttraumatic trigeminal neuropathy (n=7).

Psychophysical tests like quantitative sensory testing and qualitative sensory testing and the electrophysiological nociceptive-specific blink reflex were performed.

The scores from the Pain Catastrophizing Scale (PCS), Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory (STAI) measuring state anxiety (STAI-S) and STAI-T measuring trait anxiety, the 8-item Jaw Function Limitation Scale (JFLS-8), 4-item and 15-item Patient Health Questionnaire (PHQ-4 and PHQ-15), Oral Behaviors Checklist (OBC), and 49-item Oral Health Impact Profile (OHIP-49) were compared between the patients and a group of 20 healthy controls (10 women and 10 men, mean age 37.7 11.4 years).

The main quantitative sensory testing finding observed was an abnormal somatosensory function in 1 parameter in 94.7% of patients with damage to the nerve branches innervating the extraoral region and 88.9% of patients with damage to the nerve branches innervating the intraoral region.

Among 19 patients in whom extraoral QST was performed, at least 1 parameter with loss or gain of somatosensory function was evident in 13 patients (68.4%) on the unaffected side and in 18 patients (94.7%) on the affected side. Among 18 intraorally assessed subjects, in 15 patients (83.3%) there was at least 1 parameter with loss or gain of somatosensory function on the unaffected side and in 16 patients (88.9%) on the affected side.

Qualitative sensory testing identified a side-to-side difference in the tactile and pinprick stimulation in >77% of the patients. An abnormal nociceptive-specific blink reflex response was dependent on the trigeminal branch stimulated; abnormal findings were observed in > 71% of patients for V2 branch and > 42% for the V3 branch stimulation. No correlations were seen between any of the QST and nociceptive-specific blink reflex parameters.

Compared to the healthy participants, patients showed higher scores for pain catastrophizing (10.79.4 vs 17.413.0, P <.001), symptoms of depression (3.23.0 vs 10.29.1, P =.029) and anxiety (STAI-S: 30.17.1 vs 37.913.5; STAI-T: 33.56.2 vs 39.912.7, P =.038), limited jaw function (0.10.5 vs 15.515.5, P <.001), more somatic symptoms, and significantly impaired oral health-related quality of life.

The researchers acknowledged several study limitations, including difficult and low recruitment with potential variation in data collection, use of healthy reference data instead of age- and sex-matched controls, and lack of testing extra-trigeminal sites owing to concern for patient fatigue from multiple investigations.

The present study comprehensively quantifies and profiles the pathophysiological characteristics of trigeminal nerve damage and attests to the need of using clinical history, psychophysical, and electrophysiological investigations for diagnosis of trigeminal nerve damage, concluded the researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Pillai RS, Pigg M, List T, et al. Assessment of somatosensory and psychosocial function of patients with trigeminal nerve damage. Clin J Pain. 2020;36(5):321335. doi:10.1097/AJP.0000000000000806

More here:
Somatosensory and Psychosocial Changes Related to Trigeminal Nerve Damage - Neurology Advisor

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Chemotherapy Induced Peripheral Neuropathy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Chemotherapy Induced Peripheral Neuropathy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Chemotherapy Induced Peripheral Neuropathy market to assist our clients arrive at beneficial business decisions.

The recent published research report sheds light on critical aspects of the global Chemotherapy Induced Peripheral Neuropathy market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Chemotherapy Induced Peripheral Neuropathy market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Chemotherapy Induced Peripheral Neuropathy market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/30209

The recent published study includes information on key segmentation of the global Chemotherapy Induced Peripheral Neuropathy market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Chemotherapy Induced Peripheral Neuropathy market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Chemotherapy Induced Peripheral Neuropathy market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Chemotherapy Induced Peripheral Neuropathy Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/30209

Global Chemotherapy Induced Peripheral Neuropathy Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Chemotherapy Induced Peripheral Neuropathy market. Key companies listed in the report are:

key players and product offerings

Global Chemotherapy Induced Peripheral Neuropathy Market by Geography:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/30209

Some of the Major Highlights of TOC covers in Chemotherapy Induced Peripheral Neuropathy Market Report:

Chapter 1: Methodology & Scope of Chemotherapy Induced Peripheral Neuropathy Market

Chapter 2: Executive Summary of Chemotherapy Induced Peripheral Neuropathy Market

Chapter 3: Chemotherapy Induced Peripheral Neuropathy Industry Insights

Chapter 4: Chemotherapy Induced Peripheral Neuropathy Market, By Region

Chapter 5: Company Profile

And Continue

See more here:
Assessing the Fallout From the Coronavirus Pandemic Chemotherapy Induced Peripheral Neuropathy Market Comprehensive Survey 2019 2029 - Jewish Life...

Dose-limiting toxicities (DLTs) were minimal with the combination of canakinumab plus pembrolizumab (Keytruda), and platinum-based doublet chemotherapy in patients with advanced or metastatic nonsmall cell lung cancer who were treated in the phase II CANOPY-1 study (NCT03631199), demonstrating that the combination could be well-tolerated in these patients.1

Results from the safety run-in portion of the study were presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting. The purpose for part 1 of the CANOPY-1 study was to determine a safe dose of canakinumab for the second portion of the study.

Overall, 30 patients with previously untreated stage IIIB or IIIC or stage IV NSCLC were enrolled to the safety run-in portion of CANOPY-1. For induction therapy, patients in cohort A (n = 10) received canakinumab in combination with pembrolizumab, carboplatin and pemetrexed; cohort B (n = 11) received canakinumab plus pembrolizumab, cisplatin, and pemetrexed; and cohort C (n = 9) received canakinumab plus pembrolizumab, carboplatin, and paclitaxel. All cohorts received maintenance treatment of canakinumab, pembrolizumab, and pemetrexed.

The median age of patients was 63 years (range, 28-77), and the majority of patients were men (73.3%). Patients had an ECOG performance status of 0 (30.0%) or 1 (70.0%) and were either white (60.0%) or Asian (40.0%). Most patients were former smokers (63.3%) while some were never smokers (23.3%) and current smokers (13.3%).

Treatment was discontinued in 6 of the 30 patients (20.0%) and remained ongoing in the remaining 24 patients (80.0%). The reason for treatment discontinuation was progressive disease in 5 patients and death in 1 patient.

No serious adverse events (AEs) were fatal or considered related to canakinumab. AEs led to discontinuation of 1 of the study drugs in 3 patients (10%), all of which were included in cohort C. Hepatitis led to discontinuation of pembrolizumab, and both polyneuropathy and peripheral neuropathy led to discontinuation of chemotherapy.

A dose-limiting toxicity was observed in 1 patient within the first 42 days of therapy, which was grade 3 hepatitis and was deemed related to pembrolizumab in cohort C. The most common grade 3 AEs included pulmonary embolism in 3 patients (2 from cohort A and 1 from cohort C; 10%) and decreased neutrophil count in 2 patients (1 from each cohort; 10%).

Only 1 patient experienced a grade 4 AE, which was cardiac tamponade in cohort B, and 1 patient in cohort B died due to NSCLC.

Based on these findings, the 200-mg dose of canakinumab administered subcutaneously every 3 weeks in combination with the standard dose of pembrolizumab and a platinum-based chemotherapy doublet will be used in the next phase of the CANOPY-1 study, which will be a randomized double-blind, placebo-controlled phase III part to evaluate the safety and efficacy of the triplet regimen. Enrollment for this portion of the study was completed in January 2020 with 643 patients enrolled.

The primary end point of the study was DLTs in the first 42 days of treatment in order to determine the recommended phase III doses of canakinumab in combination with pembrolizumab and a platinum-based doublet chemotherapy. Secondary end points included objective response rate, duration of response, disease control rate, safety, and PK and immunogenicity.

A phase III clinical trial, CANOPY-A (NCT03447769), is underway to evaluate the efficacy and safety adjuvant canakinumab (ACZ885) in patients with nonsmall cell lung cancer (NSCLC) after complete surgical resection versus placebo, according to a presentation at the 2020 American Association for Cancer Research (AACR) Annual Meeting.2

The trial is designed to assess 1500 adult patients with completely resected NSCLC. The rationale for evaluating canakinumab, a monoclonal antibody against pro-inflammatory cytokine IL-1in this patient population is based on previous findings from the phase III CANTOS study, which evaluated the role of this agent in preventing cardiovascular events among patients with myocardial infarction who had an elevated C-reactive protein (CRP) level.

The clinical development of canakinumab as an antineoplastic agent is somewhat atypical as a particularly compelling piece of evidence supporting the potential clinical efficacy of canakinumab in NSCLC comes from a clinical study of an unrelated disease, said Edward B. Garon, MD, MS, director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, during his presentation at the 2020 AACR Annual Meeting.

Results from the CANTOS study, which were published in the New England Journal of Medicine in 2017, prompted interest in the agents potential as therapy in lung cancer. The trial demonstrated a highly significant reduction in lung cancer incidence, as well as mortality, in the group of patients that received canakinumab compared with placebo.3

As part of that cardiovascular study, which evaluated over 10,000 patients, the incidence and mortality from lung cancer was reduced among patients receiving canakinumab, Garon said.2 Intriguingly, this effect was dose-dependent with the greatest reduction occurring among patients treated at the highest dose level evaluated.

IL-1 is an inflammatory cytokine released by various cell types to promote tumor growth, progression, and metastasis. It upregulates tumor-association inflammation, which is known to suppress antitumor immune responses. Canakinumab targets tumor-promoting inflammation to reduce immunosuppression by binding to human IL-1 and neutralizing the activity by blocking its interaction with IL-1 receptors.2

The multicenter randomized double-blind, placebo-controlled CANOPY-A study is enrolling patients with stage IIA-IIIA and IIIB NSCLC and an ECOG performance status of 0 or 1. Patients can have any histology and must have recovered from all toxicities related to prior systemic therapy to grade 1, although patients with any grade alopecia and grade 2 or less neuropathy are allowed to enter the study as well.

If patients have unresectable or metastatic disease, they are ineligible to participate. They will also be unable to enter the study if they received neoadjuvant chemotherapy or neoadjuvant radiotherapy. If there is a presence or a history of a malignant disease besides the resected NSCLC that has been diagnosed or required therapy within the past 3 years, they could not enter the study. Patients with a history of current diagnosis of cardiac disease or uncontrolled diabetes are also ineligible.

Patients enrolled to the CANOPY-A study will undergo appropriate adjuvant therapy, which is primarily inclusive of cisplatin-based chemotherapy and in some cases radiotherapy if indicated by local guidelines or practices. Patients are randomized 1:1 to receive 18 cycles of either Canakinumab at 200 mg or placebo subcutaneously every 3 weeks.

The primary end point of the trial is disease-free survival. Secondary end points include overall survival, lung cancer-specific survival, adverse events, and EKG and laboratory abnormalities. Additional secondary end points also include PK evaluation, anticanakinumab antibodies, and health-related quality of life.

A biomarker substudy will also be conducted under CANOPY-A to determine the impact of surgical resection on biomarkers, such as CRP and cytokines. Eligibility criteria for this substudy mirror the criteria for the randomized study post-resection. Patients will undergo blood sample collection both pre- and post-surgery.

Canakinumab has already been approved by the FDA for the treatment of a spectrum of autoinflammatory conditions, such as rheumatologic disorders.3

References

See the original post here:
Canakinumab Plus Pembrolizumab and Chemotherapy Appears Safe in Advanced NSCLC - Targeted Oncology

Research report on global Neuropathy Pain Treatment Market 2020 with industry-primary research, secondary research, product research, size, trends, and Forecast.

The Neuropathy Pain Treatment report provides independent information about the Neuropathy Pain Treatment industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Neuropathy Pain Treatment Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Neuropathy Pain Treatment Market: Products in the Neuropathy Pain Treatment classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Table Of Content

Market Overview: Scope & Product Overview, Classification of Neuropathy Pain Treatment by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), Neuropathy Pain Treatment Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and Prospect

Neuropathy Pain Treatment Market by Manufacturing Cost Analysis: Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Neuropathy Pain Treatment Market Report Covers the Following Segments:

Segment by Type:

Calcium channel alpha 2-delta ligandsSerotonin-norepinephrine reuptake inhibitorsOthers

Segment by Application:

Retail PharmaciesHospitalsOthers

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Key Benefits for Stakeholders

The study provides an in-depth analysis of the Neuropathy Pain Treatment market size along with the current trends and future estimations to elucidate the imminent investment pockets.

Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.

Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.

The quantitative analysis of the Neuropathy Pain Treatment industry from 2020 to 2026 is provided to determine the Neuropathy Pain Treatment market potential.

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email:[emailprotected]

Website:http://marketresearchbazaar.com/

Blog:http://marketresearchbazaar.com/blogs

See the article here:
Neuropathy Pain Treatment Market Giants Spending Is Going To Boom - Cole of Duty

Diabetic Neuropathy Market Research Report 2020, is mostly driven by the improved taking on of Diabetic Neuropathy across small and medium-sized enterprises. Worldwide Diabetic Neuropathy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetic Neuropathy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

About Diabetic Neuropathy Market Report

This research report categorizes the global Diabetic Neuropathy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2020-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Diabetic Neuropathy Market Report:

Diabetic Neuropathy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Diabetic Neuropathy, Market Driving Factor Analysis of Diabetic Neuropathy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Diabetic Neuropathy, and Cost and Gross Margin Analysis of Diabetic Neuropathy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Diabetic Neuropathy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Diabetic Neuropathy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Diabetic Neuropathy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Read more here:
Diabetic Neuropathy Market Global Status and Business Outlook 2018 to 2026 - Latest Herald

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Diabetic Peripheral Neuropathy Treatment Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Diabetic Peripheral Neuropathy Treatment market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Diabetic Peripheral Neuropathy Treatment market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Diabetic Peripheral Neuropathy Treatment market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Diabetic Peripheral Neuropathy Treatment Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=205689&utm_source=LHN&utm_medium=888

**Our SAMPLE COPY of the report gives a brief introduction of the Diabetic Peripheral Neuropathy Treatment market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Diabetic Peripheral Neuropathy Treatment Market:

Global Diabetic Peripheral Neuropathy Treatment Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=205689&utm_source=LHN&utm_medium=888

Diabetic Peripheral Neuropathy Treatment Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Diabetic Peripheral Neuropathy Treatment industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Diabetic Peripheral Neuropathy Treatment industry.

-> Furthermore, we will help you to identify any crucial trends to predict Diabetic Peripheral Neuropathy Treatment market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Diabetic Peripheral Neuropathy Treatment market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=205689&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Diabetic Peripheral Neuropathy Treatment market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Diabetic Peripheral Neuropathy Treatment market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Diabetic Peripheral Neuropathy Treatment Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Peripheral Neuropathy Treatment Market Size, Diabetic Peripheral Neuropathy Treatment Market Growth, Diabetic Peripheral Neuropathy Treatment Market Forecast, Diabetic Peripheral Neuropathy Treatment Market Analysis

Our Trending Reports

Dozers Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Drain Cleaning Machine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Dried Botanicals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original:
Diabetic Peripheral Neuropathy Treatment Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Astellas Pharma

Global Diabetic Neuropathy Drugs Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175788&utm_source=LHN&utm_medium=888

Diabetic Neuropathy Drugs Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Diabetic Neuropathy Drugs industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Diabetic Neuropathy Drugs industry.

-> Furthermore, we will help you to identify any crucial trends to predict Diabetic Neuropathy Drugs market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Diabetic Neuropathy Drugs market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=175788&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Diabetic Neuropathy Drugs market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Diabetic Neuropathy Drugs market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Diabetic Neuropathy Drugs Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Diabetic Neuropathy Drugs Market Size, Diabetic Neuropathy Drugs Market Growth, Diabetic Neuropathy Drugs Market Forecast, Diabetic Neuropathy Drugs Market Analysis

Our Trending Reports

Sensors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

U.S. Pest Control Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Diabetic Neuropathy Drugs Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

A workplace injury two decades ago when she was newly pregnant left Robin Irvin with neuropathy in her left leg and without a functioning bowel or bladder. She has been living on disability benefits since.

Now as the coronavirus pandemic upends the economy, Ms. Irvin, 48, has found a way to get back into the work force: She is answering customer service calls for a regional retail chain.

Call centers have had to adapt swiftly because the pandemic has dealt them a double blow. They are fielding more calls from customers inquiring about online orders or seeking refunds or forbearance. But many of the people who would normally answer those calls either cant get to work or are not equipped to work from home.

The transition has been messy; industry executives say they are struggling to ship computers, headsets and other equipment to employees. Many customer service representatives, who earned a median income of $34,710 last year, also dont have internet connections fast enough to take calls and log in to corporate computer systems. In addition, companies said, they have had to shut down offices in countries like the Philippines because of strict stay-at-home orders.

Some companies, like Charter Communications, the telecom giant known as Spectrum, have come under fire for requiring workers to go to offices. More than 230 Charter employees tested positive for Covid-19, and roughly half worked in offices or call centers, according to a person with knowledge of the company who was not authorized to speak publicly. A spokeswoman said a significant majority were now working from home.

Many employers are seeking new workers wherever they can find them. One option is hiring people with disabilities.

The National Telecommuting Institute, a nonprofit that works with the Social Security Administration to fill telecommuting jobs with people who have disabilities, has been approached by nearly a dozen additional companies seeking workers in the last three weeks. The institute has handled 30 percent more job postings over the past month than it did a year ago, and the numbers could be much higher in the next month, said Alan Hubbard, the institutes chief operating officer.

Founded in 1995, the telecommuting institute trains disabled people and helps them acquire the necessary equipment and broadband connections. The group also pairs beneficiaries with mentors who help them update their rsums, prepare for interviews and make the transition to work.

Were looking at this as tremendous opportunity to place people with disabilities into jobs, Mr. Hubbard said. Right now is the time companies can fulfill the promise to the Americans With Disabilities Act.

The institute is funded by government and business partnerships. Some companies outsource staffing, payroll and other human resource functions to the nonprofit.

Ms. Irvin, who lives in Sayre, Pa., found the telecommuting institute two years ago but didnt secure a job until March. She is now taking customer service calls for Meijer, a supermarket chain that operates in the Midwest and has worked with the institute since 2005.

I feel like I have some self-worth back, she said. Many of the calls she is fielding deal with online orders, which have spiked as people avoid shopping in stores.

Since the Covid-19 crisis, N.T.I. has helped us to meet additional customer demand, Meijer said in a statement. We have found they handle both basic and escalated customer emails and calls on Meijers behalf on par or better than their peers.

Call volumes are off the charts in several industries, including health care, insurance, technology and retail, said Michele Rowan, president of Customer Contact Strategies, a consulting company that specializes in remote work and call centers.

Alorica, an outsourcing company that handles calls for large corporations, has had to temporarily shut down outposts in Guatemala, the Dominican Republic and Jamaica. Shelter-in-place orders and curfews have prevented workers in those countries from going to work, and many cant work from home because they do not have computers and broadband internet connections.

The companys U.S. operation is having to pick up that slack, said Colleen Beers, the president of North American and European operations. The company is trying to hire 8,000 people to keep up with demand.

Call center work can be grueling, and some companies that employ lower-wage, lower-skilled workers have turnover rates of 30 percent to 45 percent. Some employers said the telecommuting institutes beneficiaries were less likely to quit.

Erin Blunt, the president of VForce, which handles membership renewal, emergency roadside services and other calls for AAA, said her company hired 95 percent of its employees through the institute. N.T.I. is hiring people who really, truly want to work, she said.

Benjamin Cargile, 43, landed a job with the bank PNC last month through the institute and hopes to keep it for years.

I dont really like being on disability, said Mr. Cargile, who lives in Morrisville, N.C., and has received disability benefits since 2013 because of agoraphobia and other mental health issues. You want to be able to support yourself.

Workers like Mr. Cargile and Ms. Irvin were ready to start working because they already had the equipment and internet connections that call centers expect. That wasnt true of many people who already had call center jobs, Ms. Rowan said.

Before the coronavirus, about 80 percent of call centers let some employees work from home at least some of the time, but only about 20 percent to 40 percent of workers did so, Ms. Rowan said. A survey of 108 call centers conducted by ContactBabel, a research firm, found that 71 percent of their workers in the United States were working remotely in mid-April.

Although call centers are considered essential businesses, many sent employees home because desks are typically spaced only three to four feet apart.

Alorica has sent 60 percent of its employees worldwide home to work. Of its 16,000 U.S. employees, 78 percent are home, Ms. Beers said. The transition was slow at first because the company had to coordinate with corporate customers to figure out what kind of equipment and internet access workers would need. In some cases, telecom companies couldnt get installers to homes fast enough to set up new connections.

We didnt have the opportunity for nine weeks to figure this out, Ms. Beers said.

Some companies were able to move faster. ASK, a smaller call center operator based in Montgomery, Ala., told its agents to do speed tests on their home internet connections on March 9 and now has 430 of its roughly 450 employees telecommuting, said Rick Burley, the companys president.

The rest either prefer to work in the office or dont have broadband at home. Mr. Burley said ASKs office, a former bowling alley, allows the few employees still coming in to sit 30 to several hundred feet apart.

Industry executives said they had noticed benefits from having employees work from home. For example, fewer employees are missing shifts, Ms. Beers said.

Ms. Rowan said employers could allow as many as half their workers to continue working from home once government officials lifted stay-at-home orders. That could provide more opportunities for people with disabilities, make it easier for employees to pick up extra hours and attract people who need part-time work.

It shouldnt have taken this to happen, frankly, Ms. Rowan said.

Tina Lewis, 48 started working for Live Response Solutions from her home in Portland, Ore., through the telecommuting institute in February. While it feels odd to benefit from the pandemic, said Ms. Lewis, who has fibromyalgia and peripheral neuropathy in her legs, she is grateful.

Having Social Security income thats OK. But youre barely surviving, she said. You need another way to survive, and being able to work from home makes that possible.

Read this article:
Needing At-Home Workers, Call Centers Turn to People With Disabilities - The New York Times

In Las Vegas, one-third of the local economy depends on the leisure and hospitality industry, more than in any other major metropolitan area in the country. In other economic news, many Americans foresee their jobs coming back when pandemic tapers off, the outbreak exposes the wounds of the Great Recession, a political divide separates some essential workers and more.

The New York Times:How Las Vegas Became Ground Zero For The American Jobs CrisisWhen Valicia Anderson starts to count the people she knows in Las Vegas who have lost their jobs, she runs out of fingers fast. Her husband, the breadwinner of her family and a restaurant worker in the Rio casino. All 25 of his co-workers. Her grown son, in a temp agency. The technician who does her nails. The barber who cuts her husbands hair. Her best friend, a waitress. The three servers and a manager at the TGI Fridays that is her familys favorite treat. (Tavernise, 4/26)

The Associated Press:AP-NORC Poll: Most Losing Jobs To Virus Think Theyll ReturnOne out of every four American adults say someone in their household has lost a job to the coronavirus pandemic, but the vast majority expect those former jobs will return once the crisis passes, according to a new poll from The Associated Press-NORC Center for Public Affairs Research. The economic devastation writ by COVID-19 is clear: 26.4 million people have lost their job in the past five weeks, millions of homeowners are delaying mortgage payments and food banks are seeing lines of cars that stretch for miles. (Boak and Swanson, 4/24)

The Hill:Coronavirus Exposes Scars Of Great RecessionThe coronavirus and the desperate economic measures used to fight it are exposing some of the wounds inflicted during the Great Recession. While some Americans may be able to recover quickly when the pandemic subsides, the outbreak poses bigger threats to vulnerable communities that didnt benefit as much as others from the past 10 years of economic growth. (Lane, 4/26)

The New York Times:A Survey Of Essential Workers Shows A Political DivideDemocrats and Republicans differ on attitudes toward coronavirus risks and in workplace behaviors meant to reduce them, according to a new survey. This partisanship has the potential to hurt efforts to stop the spread of the virus. The data from Gallups Covid-19 tracking panel shows that people deemed essential workers are generating large numbers of close contacts with other people, putting themselves and those they live with at risk. Recognizing this, most workers have changed how they do their jobs to reduce the risk of viral transmission. (Rothwell, 4/27)

The New York Times:Risking My Life To Truck In Milk, Wine And Hand SanitizerJoseph Morales puts on a mask and gloves whenever he is delivering truckloads of wine, vodka and gin to a thirsty city. But he can do nothing about the person who coughs or comes too close in cramped stores. Im basically risking my life, said Mr. Morales, 41, a truck driver for a liquor distributor. If that person has it, Im doomed because Im right there. (Hu, 4/27)

The New York Times:Needing At-Home Workers, Call Centers Turn To People With DisabilitiesA workplace injury two decades ago when she was newly pregnant left Robin Irvin with neuropathy in her left leg and without a functioning bowel or bladder. She has been living on disability benefits since. Now as the coronavirus pandemic upends the economy, Ms. Irvin, 48, has found a way to get back into the work force: She is answering customer service calls for a regional retail chain. (Peiser, 4/26)

Read the original:
In Las Vegas, A City Of Tourism And Leisure, The Economic Toll Has Been Devastating - Kaiser Health News

Global Pain Management Therapeutics Market: Snapshot

Pain is invariably around whenever a body is suffering from diseases, which can be of multiple types including fibromyalgia, stomach ulcer, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Even during and after the therapy, pain constitutes a major part of the procedure that the subject has to bear but with technological advancements, it has become possible to considerably reduce the suffering and manage the pain via a variety of physiological mechanism, targeting the nociceptors for example. As the investments on robust infrastructure escalates across various emerging and developed countries, and awareness regarding the availability of alternatives increase, the demand in the global pain management therapeutics market is projected to increment at a healthy CAGR during the forecast period of 2017 to 2025.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1724

Currently, the developed regions of North America and Europe serve the maximum demand in the pain management therapeutics market, although highly populated emerging economies in Asia Pacific such as India and China are expected to turn into a profitable market towards the end of the forecast period.

In the current scenario, the global pain management therapeutics market is highly competitive, with the leading players constantly striving to come up with new products that are more efficient and hence gives them an edge over their competitors. In the current scenario, Purdue Pharma LP and Pfizer lead the market with nearly half the global shares, although the likes of Depomed Inc. and AstraZeneca Plc gaining ground. There is a strong presence of conventional medicines for pain management, which will keep the competitive landscape saturated throughout the forecast period. In the near future, a number of medium and small generic drugs manufacturers are expected to have a foray into pain management therapeutics market too, which will further intensity the tussle for the pole position.

Pain Management Therapeutics Market: Overview

Pain management therapeutics comprise various methods to ease varied degrees of pain among patients and improve their quality of life. Pharmaceutical therapeutics are usually the first line of treatment for pain management and if this does not work, patients opt for other methods such as pain managing devices, physiotherapy, and chiropractic therapy.

Pain management therapeutics can be categorized into antidepressants, anticonvulsants, opioids, anesthetics, antimigraine agents, non-steroidal anti-inflammatory drugs (NSAIDS), and non-narcotic analgesics. Various drugs are used for the management of different kinds of pain, such as fibromyalgia, neuropathic pain, arthritic pain, chronic back pain, post-operative pain, migraine, and cancer-related pain. A common trend that has been observed among patients is the consumption of over-the-counter (OTC) drugs rather than prescription drugs.

Pain Management Therapeutics Market: Trends

The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate. In addition to this, a massive geriatric population susceptible to arthritis, nerve damage, neuropathy, and joint pain is also boosting the market for pain management therapeutics. Supplementing market growth are favorable regulatory scenarios in many developed countries around the world.

However, as more and more patients opt for generic pain management drugs, the branded segment has been suffering a major setback. Moreover, the patent expiries of a number of blockbuster drugs will have a significant impact on the overall market for pain management therapeutics.

Pain Management Therapeutics Market: Market Potential

Despite the fact that leading brands are nearing a point of saturation, the pain management therapeutics market possesses strong potential for growth, particularly for smaller players. For instance, looking to expand its footprint in the global market as well as strengthen its U.S. pharmaceutical unit, Ireland-based Endo International plc acquired Auxilium Pharmaceuticals in 2015. The company also launched the BELBUCA Bucccal Film in 2016, which is used for the management of chronic pain.

Purdue Pharma, headquartered in Connecticut, U.S., ventured into a patent agreement with Acura Pharmaceuticals, Inc. and Egalet Corporation in 2016 for the development and sales of opioid pain management medicines.

Pain Management Therapeutics Market: Regional Outlook

Geographically, the global market for pain management therapeutics comprises North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. North America and Europe hold the largest share in the overall market and are slated to continue their dominance throughout the forecast period. The rising consumption of advanced pain management drugs and the availability of well-established and sophisticated healthcare infrastructure are the key factors driving the North America and Europe pain management therapeutics market. Asia Pacific is an immensely lucrative region and a number of players are looking to expand their operations in the many emerging countries in the region. This can be attributed to strong economic growth in nations such as China, India, Malaysia, and Japan, rising investments in the healthcare industry in these countries, and the increasing affordability of the population.

Pain Management Therapeutics Market: Competitive Analysis

There are a host of generic as well as branded drug manufacturers in the global pain management therapeutics market. These include GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Abbott Laboratories, AstraZeneca, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Purdue Pharma L.P., Endo Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Depomed, Inc., and Pfizer, Inc. Although companies producing branded pain management therapeutics have a strong foothold in the market, the market is actually dominated by generic drug manufacturers, giving small- and medium-scale players immense scope for growth.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/pain-management-therapeutics-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original here:
Pain Management Therapeutics Market Worldwide Survey On Product Need 2025 - Latest Herald

As of April 2020, there are 35 states that have legalizedmedicinal cannabis to some extent and of course, this varies greatly fromstate to state.

Despite the federal government keeping cannabis listed as a Schedule 1 narcotic, each state has the authority to create their own laws governing cannabis use within their borders. Most states allow the herb now, but the qualifying conditions that allow patients access to medical cannabis are different in each state. Use our guide to determine whether you qualify for medical cannabis in your home state.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.akleg.gov/basis/Bill/Plaintext/21?Hsid=SB0094E

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and post-traumatic stress disorder.

Click here for the full list and for any updates http://www.azleg.gov/viewdocument/?docName=http://www.azleg.gov/ars/36/02801.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://www.healthy.arkansas.gov/Pages/MedMarijuana.aspx

**Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any other chronic or persistent medical symptom that considerablylimits a persons abilities or diminishes their quality of life, as defined bythe Americans with Disabilities Act of 1990.

Click here for the full list and for any updates https://leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?lawCode=HSC&division=10.&title=&part=&chapter=6.&article=2.5.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), persistent muscle spasms, seizures, severenausea, and severe pain, as well as any condition that is approved by a doctor.

Click here for the full list and for any updates https://www.colorado.gov/pacific/cdphe/qualifying-medical-conditions-medical-marijuana-registry

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

For underagepatients:

Click here for the full list and for any updates http://www.ct.gov/dcp/cwp/view.asp?q=509628&dcpNav=%7C

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

Any chronic or debilitating conditions including but notlimited to: cachexia (wasting syndrome), severe pain that has not responded toprescribed medication in 3 months, recurring nausea, muscle spasms, andmultiple sclerosis.

Click here for the full list and for any updates http://dhss.delaware.gov/dph/hsp/medmarpt.html

*Recreational cannabis is legal in this district

Qualifying medical conditions include:

Any other condition that is chronic, that could benefit frommedical cannabis (as determined on a case-by-case basis) and cannot beeffectively treated by standard medical practices.

Click here for the full list and for any updates: http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/140523MMPRegulationsRevised.pdf

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399/0381/Sections/0381.986.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but not limitedto: cachexia (wasting syndrome), severe pain, severe nausea, seizures, musclespasms, multiple sclerosis, and Crohns disease.

Click here to read the full list and for any updates http://health.hawaii.gov/medicalcannabisregistry/providers/debilitating-medical-conditions/

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Click here forthe full list and for any updates http://www.dph.illinois.gov/topics-services/prevention-wellness/medical-cannabis/debilitating-conditions

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list and for any updates list of guidelines http://www.state.ia.us/odcp/docs/CBDFinalFactSheetIowaJune2014.pdf

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list or for any updates http://ldh.la.gov/index.cfm/page/3633

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Sec. 19. 22 MRSA2423-B

Click here for afull list or for any updates https://legislature.maine.gov/legis/bills/bills_128th/billtexts/HP106001.asp

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for the full list and for any updates http://mmcc.maryland.gov/Pages/patients.aspx

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other debilitating condition as determined by a qualified physician.

Clickhere for the full list and for any updates https://malegislature.gov/Laws/SessionLaws/Acts/2012/Chapter369

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

A chronic ordebilitating including but not limited to: cachexia (wasting disease), severeand chronic pain, severe nausea, seizures, muscle spasms, and multiplesclerosis.

Click here for thefull list or for any updates http://www.legislature.mi.gov/(S(vxeekwsfu2lon4z4ssftgnjt))/mileg.aspx?page=getObject&objectName=mcl-333-26423

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other medical condition thats approved by the medicalcommissioner

Click here for the full list or for any updates http://www.health.state.mn.us/topics/cannabis/patients/conditions.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other chronicor debilitating medical condition that can benefits from the use of medicalcannabis, as determined by a qualified physician.

Click here forthe full list or for any updates https://health.mo.gov/safety/medical-marijuana/faqs.php

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here forthe full list or for any updates http://dphhs.mt.gov/marijuana/mmpfaq#159692088-what-are-the-debilitating-conditions-for-which-i-can-recommend-marijuana-for-my-patients

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://dpbh.nv.gov/Reg/MM-Patient-Cardholder-Registry/dta/FAQs/Medical_Marijuana_Patient_Cardholder_Registry_-_FAQs/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.dhhs.nh.gov/oos/tcp/medical-conditions.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://nj.gov/health/medicalmarijuana/pat_faqs.shtml#7

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://nmhealth.org/publication/view/form/135/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://www.health.ny.gov/regulations/medical_marijuana/faq.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.legis.nd.gov/assembly/65-2017/documents/17-0630-05000.pdf

*Recreational cannabis is NOT legal in this state

The rest is here:
What Are The Qualifying Medical Conditions For Cannabis In Your State? - CBD Testers

Optic Neuropathy Pipeline Review, H1 2019>This report offers a detailed view of market opportunity by end user segments, product segments, sales channels, key countries, and import / export dynamics. It details market size & forecast, growth drivers, emerging trends, market opportunities, and investment risks in over various segments in Optic Neuropathy industry. It provides a comprehensive understanding of Optic Neuropathy market dynamics in both value and volume terms.

The key players covered in this study > Allergan Plc, Antoxis Ltd, Quark Pharmaceuticals Inc, Recursion Pharmaceuticals Inc, Regenera Pharma Ltd, Regeneron Pharmaceuticals Inc

The final report will add the analysis of the Impact of Covid-19 in this report Optic Neuropathy industry.

Get Sample Copy of the Complete Report

This report focuses on the global Optic Neuropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Optic Neuropathy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Table Of Content

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 North America

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

This report studies the Optic Neuropathy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Optic Neuropathy market by product type and applications/end industries.

Customization of this Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. For more relevant reports visitwww.reportsandmarkets.com

What to Expect From This Report on Optic Neuropathy Market:

The developmental plans for your business based on the value of the cost of the production and value of the products, and more for the coming years.

A detailed overview of regional distributions of popular products in the Optic Neuropathy Market.

How do the major companies and mid-level manufacturers make a profit within the Optic Neuropathy Market?

Estimate the break-in for new players to enter the Optic Neuropathy Market.

Comprehensive research on the overall expansion within the Optic Neuropathy Market for deciding the product launch and asset developments.

If U Know More about This Report

Any special requirements about this report, please let us know and we can provide custom report.

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

For more detailed information please contact us at:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

More here:
Optic Neuropathy Market by Top Manufacturers with Production, Price, Revenue (value) and Market Share to 2026 - Latest Herald

Peripheral neuropathy is a common complication of primary Sjgren syndrome and may be associated with a diminished health-related quality of life (HR-QoL), according to research results published in Rheumatology International.

Researchers sought to compare HR-QoL outcomes in patients with primary Sjgren syndrome, both with and without peripheral neuropathy. They also aimed to examine the associations between the neurologic complications and components of HR-QoL outcomes using the 36-item Short Form Health Survey (SF-36). Overall, 50 adult patients with primary Sjgren syndrome (median age, 57.5 years; 96% women) were included in the study.

Of the total cohort, 80% (n=40) reported subjective symptoms, including paresthesia or other symptoms that were suggestive of neuropathic pain on a periodic or permanently present basis. In total, 46% (n=23) of patients met the criteria for a diagnosis of peripheral neuropathy (PNS+); the remaining patients were referred to as PNS-.

Researchers indicated the most common peripheral nervous system manifestation to be sensorimotor neuropathy, which was present in 47% of patients who were PNS+. Mononeuropathy was present in 26%, pure axonal sensory neuropathy, axonal motor neuropathy, and small fiber neuropathy were each present in 4.3%, and cranial nerve involvement was present in 17.4% of patients who were PNS+; 1 patient experienced both cranial and sensorimotor neuropathy. Among 35% of patients who were PNS+, neurologic symptoms preceded patients diagnosis of primary Sjgren syndrome.

Investigators studied data from both groups of patients in terms of clinical characteristics and laboratory testing results, and observed similarity in age, disease duration, time from diagnosis, and time of symptom onset. Clinical manifestations, including parotid enlargement, respiratory tract involvement, lymphadenopathy, and hypocomplementemia were significantly more prevalent among patients who were PNS+ vs those who were PNS- (74% vs 44%; 65% vs 37%; 61% vs 19%; and 26% vs 7%, respectively). In addition, patients in the PNS+ vs PNS- group were statistically significantly more likely to frequently use cyclophosphamide because of extraglandular manifestations (17% vs 0%, respectively).

Both groups were also compared based on the results of the visual analog scale (VAS)-pain scale, SF-36, and an interview regarding pain type. Among patients who were PNS+ vs PNS-, median VAS-pain was 3 vs 0, respectively (range, 0-7; P =.229). Neuropathic type pain was often observed across both subgroups but was predominantly among patients who were PNS+ compared with those who were PNS- (70% vs 41%).

Across the 5 domains of the SF-36, patients who were PNS+ vs PNS- had significantly lower results in terms of physical and emotional roles, vitality, bodily pain, and general health (P .05).

Study limitations included potential referral bias in patient selection, researchers inability to conduct neurophysiologic testing in individuals suspected of pure small-fiber neuropathy, and a lack of unambiguous differentiation between Sjgren syndrome-related neuropathy and other forms of neuropathy.

Our study showed that peripheral nervous involvement is frequent in [patients with primary Sjgren syndrome] and it is correlated with worse HR-QoL, the researchers concluded. To get the complete picture of [patients with Sjgren syndrome], a holistic approach starting with a comprehensive assessment of disease activityis needed.

Reference

Jasklska M, Chylinska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjgrens syndrome: A preliminary report [published online March 14, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04543-2

Go here to see the original:
Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome - Rheumatology Advisor

Dont be surprised if the next time you see Elias Theodorou compete, hes a different fighter than he was in the UFC.

The Spartan parted ways with the promotion last May coming off of a loss to Derek Brunson at UFC Ottawa, despite that being his first loss in four fights and his overall UFC record standing at 8-3. In those 11 appearances, Theodorou only logged two finishes his last in March 2015 and that lack of an exclamation point on his performances may have contributed to his departure.

In February, Theodorou became the first MMA fighter to receive a therapeutic use exemption for medical cannabis, which was granted to him by the British Columbia Athletic Commission. The 31-year-old Canadian has long been an advocate for the use of cannabis as a medical treatment and he has used it to help him to deal with bilateral neuropathy pain that affects his arms and hands.

Theodorous condition influenced his approach to his UFC fights, with cannabis strictly prohibited in competition under USADA guidelines, and he spoke about how much being able to self-medicate will benefit him in the future.

I have bilateral neuropathy, so nerve damage of my upper extremities, Theodorou said on Mondays episode of The A-Side live chat. My actual hands are where the issues are and a lot of my fighting style over the last couple of days was actually taking that into account and moving around it.

Now, being able to medicate and not having those flare-ups that I normally have, because again putting your body through not only training and the condition that I already have and also the weight cut itself inhibits my ability to compete at a level playing field.

Theodorou said that medical cannabis is useful both for calming his nerves and dealing with the pain management of a competitive fighting career. Athletes in pro sports are often prescribed opioids, pain killers, and other drugs to address their maladies, and Theodorou believes adding cannabis to that list is a matter of medical equality.

While he may have utilized different tactics inside the octagon with his bilateral neuropathy unchecked, Theodorou isnt blaming his three UFC losses on not being allowed to medicate with cannabis.

I fought some really tough guys and I won more than Ive lost many times over, Theodorou said. The ones that I lost I wouldnt chalk it up to anything in regards to inability to medicate. Each individual fight is each individual situation, so Id never use an excuse, the better man won I would say. But again, the only people that Ive ever lost to were top-10 in the world at the time, and one of those persons happened to be Thiago Santos. Even in that situation I was able to take everything he threw at me and never quit.

One of the things I was able to learn from it is that even as a professional fighter, fight or flight is kind of still ingrained in us. Even when push comes to shove, I can still fight under the worst situations and in the bloodiest of wars.

In celebration of 4/20 the April 20 celebration widely recognized by cannabis culture Theodorou was hoping to fight in April in British Columbia, where he was granted his exemption, though a bout was never finalized. Wherever he competes next, Theodorou is optimistic that his TUE will carry over to other jurisdictions.

Because of the way that the whole system works in regards to the commissions, now that I got a therapeutic use exemption in one jurisdiction, most if not all should validate my exemption because of the way it all works out, Theodorou said. The case in point would be if someone got suspended for steroid use and they were suspended for a year in, lets say, New York, California wouldnt allow them to get registered until their suspension is over.

Well, the same thing happens in positive rulings. Thats the case in regards to my therapeutic use exemption. Theres already preliminary conversations with other commissions that, again, once I get a fight booked in that area theyll most likely validate my therapeutic use exemption. Obviously, it was a lot of hard work and it was able to [happen] because of me arguing my fundamental Canadian right to medicate as prescribed by my doctor in B.C., but now because of that ruling Im able to take that precedent and run with it not only in B.C. but everywhere else I fight.

Theodorou has already fought once since leaving the UFC, picking up a third-round finish against fellow big show vet Hernani Perpetuo at a show in Windsor, Ontario, last December. According to Theodorou, he was not tested for cannabis ahead of that fight and being able to self-medicate made a world of difference.

In reality, that was the first fight I was able to medicate as prescribed by my doctor and obviously, the results show for themselves, Theodorou said. Competing at the highest level at the way I was because of the strict testing, in many ways I was competing at a disadvantage compared to other athletes that can medicate as prescribed by their doctors. So now with the TUE and other avenues to compete on a competitive playing field, Im excited to keep that win streak going and smash the next person that stands in front of me.

See the rest here:
Elias Theodorou: Fighting style was affected by bilateral neuropathy before receiving cannabis TUE - MMA Fighting

Analysis Report on Neuropathic Pain Management Market

A report on global Neuropathic Pain Management market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Neuropathic Pain Management Market.

Request Sample Report @https://www.mrrse.com/sample/8659?source=atm

Some key points of Neuropathic Pain Management Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Neuropathic Pain Management Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Neuropathic Pain Management Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Neuropathic Pain Management market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Neuropathic Pain Management market is analyzed and depicted in the report.

The global Neuropathic Pain Management market segment by manufacturers include

Segmented as Follows:

This report covers the global neuropathic pain management market performance in terms of revenue contribution from various segments. The report begins with an overview of the neuropathic pain management and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the neuropathic pain management market along with detailing its opportunity analysis.

The global neuropathic pain management market is segmented based on drug class, indication, distribution channel and region. On the basis of drug class, the market has been segmented as tricyclic anti-depressants anticonvulsants, serotoninnorepinephrine reuptake inhibitor, capsaicin cream, local anaesthesia, opioids, steroids and others.

On the basis of indication, the market is segmented as diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others.

On the basis of distribution channel, the market is segmented as hospital pharmacies, retail pharmacies and online pharmacies.

A detailed analysis has been provided for each region in terms of market size, BPS analysis, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The regional market dynamics provide the key growth driver, restraints, and trends pertaining to each region. The forecast of the neuropathic pain management market by country, drug class, indication, distribution channel are represented in the tabular form for each region. This section also helps to understand the opportunity of the neuropathic pain management market in major countries by each segment.

In the next section of the report, the Competitive Landscape is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players in the neuropathic pain management market are also provided in the report, which highlights company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 20182026 and sets the forecast within the context of the neuropathic pain management market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections by drug class, indication, distribution channel evaluate the historic market analysis for the period of 20132017 and growth prospects of the neuropathic pain management market for the period 20182026. We have considered 2016 as the base year and provided data for the forecast period.

The final section of report represents the global scenario for the neuropathic pain management market along with Y-o-Y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the neuropathic pain management market and the opportunity analysis for each year over the forecast period.

Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the neuropathic pain management market over 20182026. While forecasting the market size, we have considered the impact of several factors such product approvals for neuropathic pain management, R&D investment by major players, pipeline analysis, penetration of products in different distribution channel, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/8659?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Neuropathic Pain Management economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/8659?source=atm

Benefits of Purchasing Neuropathic Pain Management Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the original post:
COVID-19: Responding to the business impacts of Neuropathic Pain Management Revenue Growth Predicted by 2019-2028 - Jewish Life News

Pain is inevitable but can be managed This often results in a way of numbness, or lack of sensation. However, in some cases when this technique is injured, individuals experience pain within the affected region. Neuropathic pain doesnt start abruptly or resolve quickly; its a chronic condition that results in persistent pain symptoms. for several patients, the intensity of their symptoms can wax and wane throughout the day. Although neuropathic pain is assumed to be related to peripheral nerve problems, like neuropathy caused by diabetes or spinal stenosis, injuries to the brain or medulla spinalis also can cause chronic neuropathic pain.

Neuropathic pain is often contrasted to nociceptive pain, which is that the sort of pain which occurs when someone experiences an acute injury, like smashing a finger with a hammer or stubbing a toe when walking barefoot. this sort of pain is usually short-lived and typically quite aware of common pain medications in contrast to neuropathic pain.

Tramadol is a medication that is available online and can be used to relieve pain.

Tramadol without prescription in USA is available on the web if you want to check it out

Anything that results in loss of function within the sensory systema nervosum can cause neuropathic pain. As such, nerve problems from carpal tunnel syndrome or similar conditions can trigger neuropathic pain. Trauma, causing nerve injury, can cause neuropathic pain. Other conditions that may predispose patients to develop neuropathic pain include diabetes, vitamin deficiencies, cancer, HIV, stroke, MS, shingles, and cancer treatments.

Neuropathic pain may be a painful condition thats usually chronic. Its usually caused by chronic, progressive nerve disease, and it also can occur because of the results of injury or infection.

If youve got chronic neuropathic pain, it can flare up at any time without a clear pain-inducing event or factor. Acute neuropathic pain, while uncommon, can occur.

Typically, non-neuropathic pain (nociceptive pain) is thanks to an injury or illness. for instance, if you drop an important book on your foot, your system a Nervo sum sends signals of pain immediately after the book hits.

With neuropathic pain, the pain isnt typically triggered by an occasion or injury.

People with this painful condition may experience shooting, burning pain. The pain could also be constant or may occur intermittently. a sense of numbness or a loss of sensation is common, too.

Neuropathic pain tends to urge worse over time. About 1 in 3 Americans experience chronic pain. Of those, 1 in 5 experience neuropathic pain.A 2014 study estimated that as many as 10 percents of USA citizens experience some sort of neuropathic pain.

Understanding the possible causes can assist you to find better treatments and ways to stop the pain from getting worse over time.Nerve Pain & Nociceptive PainYou can have nerve pain and nociceptive pain together. Both pain types are often caused by an equivalent condition.

Nerve pain is a smaller amount likely than nociceptive pain to be helped by traditional painkillers like paracetamol, anti-inflammatories, and codeine. However, other sorts of medicines often work well to ease the pain. Nerve pain is usually eased by anti-depressant or anti-epileptic medicines. Please ask your doctor for more advice.

There are pain medication like Tramadol COD available from many online pharmacies and can be bought easily

View original post here:
Nerve Pain: Know Everything About it - Living Gossip